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Abstract
Background: Lung cancer is the leading cancer diagnosis worldwide and the number one cause of cancer deaths.
Exposure to cigarette smoke, the primary risk factor in lung cancer, reduces epithelial barrier integrity and increases
susceptibility to infections. Herein, we hypothesize that somatic mutations together with cigarette smoke generate
a dysbiotic microbiota that is associated with lung carcinogenesis. Using lung tissue from 33 controls and 143
cancer cases, we conduct 16S ribosomal RNA (rRNA) bacterial gene sequencing, with RNA-sequencing data from
lung cancer cases in The Cancer Genome Atlas serving as the validation cohort.
Results: Overall, we demonstrate a lower alpha diversity in normal lung as compared to non-tumor adjacent or
tumor tissue. In squamous cell carcinoma specifically, a separate group of taxa are identified, in which Acidovorax is
enriched in smokers. Acidovorax temporans is identified within tumor sections by fluorescent in situ hybridization
and confirmed by two separate 16S rRNA strategies. Further, these taxa, including Acidovorax, exhibit higher abundance
among the subset of squamous cell carcinoma cases with TP53 mutations, an association not seen in adenocarcinomas.
Conclusions: The results of this comprehensive study show both microbiome-gene and microbiome-exposure
interactions in squamous cell carcinoma lung cancer tissue. Specifically, tumors harboring TP53 mutations, which can
impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated
tumors of this type. Given the significant need for clinical diagnostic tools in lung cancer, this study may provide novel
biomarkers for early detection.
Keywords: Lung cancer, Microbiome, TP53, Squamous cell carcinoma, Mutation
Background
Lung cancer is the leading cancer diagnosis worldwide
(1.8 million/year) and has a higher mortality than that of
the next top three cancers combined (158,080 vs 115,760
deaths) [1]. Unfortunately, lung cancer survival remains
poor and has shown minimal improvement over the past
five decades, owing to diagnosis at advanced stage and
resistance to standard chemotherapy [2]. While we have
made significant strides with targeted receptor therapy
and immunotherapy, biomarkers with higher specificity
would improve diagnosis and treatment for these
individuals.
Epidemiological evidence indicates an association be-
tween repeated antibiotic exposure and increased lung
cancer risk; however, the contribution of the lung micro-
biome to lung cancer is unknown [3]. The first line of
defense against inhaled environmental insults, including
tobacco smoke and infection, is the respiratory epithelium.
Until recently, healthy lungs were regarded as essentially
sterile; however, studies now illustrate the presence of a
lung microbiota [4], the community of microscopic
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organisms living within the host lung, which is altered in
respiratory diseases including asthma, chronic obstructive
pulmonary disease (COPD), and cystic fibrosis [5]. Disrup-
tion of the epithelium by tobacco smoke can be a primary
cause of inflammatory pathology, which is seen in both
COPD and lung cancer. Dysbiosis has been observed in
both humans and model systems of COPD and cystic
fibrosis [6, 7]. In COPD patients and in vitro, cigarette
smoke has been shown to reduce epithelial integrity and
cell–cell contact, which can increase susceptibility to re-
spiratory pathogens or other environmental pollutants [8].
Disturbances in the microbiome, from cigarette smoke,
epithelial damage, or gene mutations, can allow patho-
genic species to dominate the community or increase
virulence of other normally commensal microbes.
Evidence of this has been demonstrated in patients with
cystic fibrosis who have more virulent forms of P. aerugi-
nosa [9]. These inflammatory associated events have been
proposed to lead to an increased risk or progression of
diseases, including lung cancer.
Several bacteria are associated with chronic inflamma-
tion and subsequent increased risk of lung and colon
cancer, including Mycobacterium tuberculosis (lung can-
cer) [10], Bacteroides fragilis, and Fusobacterium nuclea-
tum (colon cancer) [11]. Recent microbiome studies in
colon cancer have demonstrated a contribution of
bacteria to carcinogenesis. Specifically, F. nucleatum, a
bacterium commonly isolated from patients with inflam-
matory bowel disease, may be a risk factor for colon can-
cer [11, 12]. The more virulent strains of F. nucleatum
affect colon cancer progression in animal models and
increase tumor multiplicity [13] by various mechanisms
including favoring the infiltration of tumor-promoting
myeloid cells to create a pro-inflammatory environment
[14]. Colorectal carcinomas associated with high
abundance of fecal F. nucleatum were found to have the
highest number of somatic mutations, suggesting that
these mutations create a pathogen-friendly environment
[15]. Similarly, B. fragilis can secrete endotoxins that
cause DNA damage leading to mutations and colon
cancer initiation [16]. Furthermore, the loss of the onco-
genic protein p53 in enterocytes impairs the epithelial
barrier and allows infiltration of bacteria resulting in
inflammatory signaling (NF-κB), which is required for
tumor progression [17]. The tumor suppressor gene
TP53 is the most commonly mutated gene in lung can-
cer [18], with certain missense mutations showing gain
of oncogenic function [19]; however, the relationship
between TP53 and microbiota in lung cancer remains
unknown. Herein, we hypothesize that somatic muta-
tions together with environmental exposures are corre-
lated with tissue-associated alterations in the microbial
community of the lung, which may participate in lung
carcinogenesis.
Results
To investigate the lung mucosal-associated microbial
alterations in the etiology of lung cancer, we analyzed
samples from the NCI-MD case-control study (n = 143
tumor and n = 144 non-tumor adjacent tissues) and lung
cancer samples from The Cancer Genome Atlas (TCGA;
n = 1112 tumor and non-tumor adjacent RNA-sequencing
[RNA-seq] data from tissues) for validation. In addition,
we used the clinical information from these two sample
populations to control for confounders in lung cancer risk
and progression (age, gender, smoking, race, family and
medical history, and co-morbidities), as well as factors that
are known to alter the human microbiome (antibiotics
and neoadjuvant therapy). Given the paucity of healthy
lung tissue available for study, we utilized two separate
tissue biorepositories. Non-cancerous lung tissue was
obtained by lung biopsy from individuals with benign lung
nodules without cancer or non-cancer lung from
immediate autopsy [20], which was used as a referent
control (Table 1).
Given the high potential for contamination in
low-biomass samples, such as the lung, we took several
measures to address this issue controlling for contamin-
ation points in the collection process. To assess possible
confounding with sequence quality, we conducted
sequencing quality control analysis by Phred score and
by sequencing run (Additional file 1: Figure S1). In order
to remove possible contaminants from our analysis, we
first performed a threshold analysis similar to a previous
study [21], wherein we plotted the mean percent
abundance across experimental samples versus negative
control samples and removed those that were ≥ 5% in
both experimental and negative control samples
(Additional file 1: Figure S2). We next applied a statis-
tical analysis wherein we used a systematic removal
process of putative contaminants including Herbaspiril-
lum, Halomonas, and Shewanella (Additional file 1:
Table S1). At each stage of removal, we report the num-
ber of Mann–Whitney p values < 0.05 comparing paired
tumor normal samples showing the greatest rise the
number of significant p-values with the removal top five
contaminants (Additional file 1: Table S1). At each stage
of removal, we report the number of Mann–Whitney
p values < 0.05 comparing paired tumor normal sam-
ples showing the greatest rise the number of significant
p values with the removal top five contaminants
(Additional file 1: Table S1). Additionally, we conducted
hierarchal clustering of negative controls, non-tumor
samples, and tumor samples independently in order to
visualize and identify the strongest sources of contamin-
ation (Additional file 1: Figures S2 and S3). The com-
bination of these analyses resulted in initial removal of
the genera Halomonas, Herbaspririllium, Shewanella,
Propionibacterium, and Variovorax.
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To identify the microbial communities present in each
tissue type, we sequenced the V3–V5 16S ribosomal RNA
(rRNA) bacterial gene using the Illumina MiSeq platform.
After quality filtering and contaminant removal, 34 mil-
lion quality sequences were retained for operational taxo-
nomic unit (OTU) clustering and downstream analysis
(Additional file 1: Table S2).
To enable us to validate findings from our NCI-MD
16S rRNA gene sequencing analysis, we took advantage
of the TCGA lung cancer database. Using the unmapped
RNA-seq reads from these samples (N = 1112 and n =
106 paired tumor/non-tumor), we analyzed with our
metagenomics analysis pipeline. After removal of all
human reads, we took the remaining non-human reads
Table 1 Descriptive summary of population samples
Control lung NCI-MD study TCGA study
ImA HBa Normal adjacent Tumor Normal adjacent Tumor
(n = 33) (n = 16) (n = 144) (n = 143) (n = 108) (n = 974)
Age - mean (SD) 39.5 (18.8) 62.6 (7.7) 65.5 (9.8) 65.7 (9.9) 66.9 (9.9) 66.4 (9.2)
< Mean 18 9 70 63 49 396
≥Mean 15 7 74 80 59 578
Unknown 5 128
Gender
M 25 11 92 87 58 514
F 8 5 52 56 45 355
Unknown 5 105
Raceb
EA 27 14 86 95 90 650
AA 5 2 58 48 8 42
Other 59
Unknown 1 10 223
Smoking statusb
Ever 14 122 127 90 768
Former 11 44 40 71 551
Current 3 64 70 19 217
Never 2 9 7 7 120
Unknown
Stage
I (a/b) 69 52 454
II (a/b) 44 28 231
III (a/b) 11 19 155
IV 2 3 29
Unknown 16 6 105
Histology
AD 67 58 485
SCC 47 50 489
Other 29
TP53 mutation status
Wild-type (AD/SCC) 32/11 125/59
Mutant (AD/SCC) 29/35 104/118
Unknown 36 568
aTwo cases removed due to emphysema
bSmoking status and race self-reported
ImA immediate autopsy, HB hospital biopsy
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and used three separate tools, MetaPhlAn, Kraken, and
PathoScope, to assign reads to taxonomy, including
bacteria, virus, and fungi (Additional file 1: Table S2).
Due to the highly curated database of PathoScope, we
were able obtain to species and in some cases
strain-level putative identification of RNA-seq reads. For
this reason, and due to its rigorous validation in other
studies [22], we used these data as our validation dataset.
Unfortunately, given that all patients in this database
had lung cancer, we could not validate our microbial
findings in non-diseased lung tissue in the TCGA data-
set. Given that this was one of the first times TCGA was
used to completely profile the microbiota of lung cancer,
we asked how similar the 16S rRNA gene sequencing
and RNA-seq microbial communities were at the
phylum and genus levels. Using an overall threshold of
0.01% of genus level abundance, we identified 236
overlapping genera out of 520 total genera in the 16S
rRNA gene sequencing data and 609 total genera in the
RNA-seq data (Additional file 1: Figure S4).
Bacterial profile of the lung cancer microbiome is
dominated by Proteobacteria and validated in a separate
lung cancer data set
We know from previous microbial studies of lung disease
that bacterial composition shifts occur compared to
normal non-diseased lungs [23] and associated with dis-
ease severity [24]; however, these compositional changes
have not been examined in lung cancer. In order to
identify the microbial changes associated with lung cancer,
we first examined the ecological diversity within samples
(alpha diversity) and between samples (beta diversity) of
non-cancerous (immediate autopsy and hospital biopsy)
tissues, non-tumor adjacent (NT) and tumor (T) tissues
from 16S rRNA gene sequencing. At the phylum level,
we observed increases in Proteobacteria (Kruskal–Wallis
p = 0.0002) and decreases in Firmicutes (Kruskal–Wallis
p = 0.04) in lung tissue hospital biopsies, as well as in
tumor and associated non-tumor tissues from the
NCI-MD study compared with non-cancer population
control lung tissues, as has been seen in COPD [25]
(Fig. 1a). Further, we note higher Fusobacterium in ImA
and HB controls as compared to cancer cases, though it is
unclear what this finding indicates at the phylogenic level.
We also observed a similar increase in Proteobacteria
(Mann–Whitney p = 0.02) between non-tumor lung tissue
and lung cancer in the TCGA study, indicating that this is
recurrent phenomenon in lung cancer (Fig. 1a). However,
the lack of similarity between the NCI-MD and TCGA
non-tumor samples may be attributed to the TCGA data
being derived from multiple sample populations in the
United States, differences in sample prep and in sequen-
cing platforms, as illustrated by Meisel et al. [26].
To identify ecological diversity changes associated with
lung cancer, we next examined the richness (Chao1) and
diversity (Inverse Simpson) of the microbiome within
samples (alpha diversity) of non-disease (immediate
autopsy and hospital biopsy) lung tissues, non-tumor
adjacent tissues, and tumor tissues from 16S rRNA gene
sequencing (NCI-MD study). Specifically, Chao1 measure-
ment demonstrated a significant increase in both tumor
and non-tumor tissue richness as compared to immediate
autopsy control tissue samples (Fig. 1b). Similarly, using
the Inverse Simpson index, which measures number (rich-
ness) and abundance (evenness) of species, we observed a
significant increase in alpha diversity in both tumor and
non-tumors as compared to hospital biopsy control tissues
(Fig. 1b), similar to studies of severe COPD [27], indicat-
ing that microbial diversity of lung cancer tissues is altered
from its non-diseased state. When we examined tissue
from cancer cases, alpha diversity was significantly differ-
ent between tumor and non-tumors in the NCI-MD study
and TCGA study, but results were not consistent between
studies or diversity metrics (Additional file 1: Figure S5).
However, we did not see any significant changes in
alpha diversity by smoking status (never, former, or
current) nor correlation with time since quitting smok-
ing (Additional file 1: Figure S4), in cancer-free or lung
cancer tissues as has been demonstrated in other lung
microbiome studies [28, 29].
We also asked whether there were differences between
microbial communities using beta diversity (Bray Curtis).
Since we were comparing between studies and between
types of sequencing (16S rRNA and RNA-seq), we used a
method that could be commonly applied between studies,
which excludes phylogeny (e.g. Bray Curtis). Within the
NCI-MD study, we observed significant differences in beta
diversity between all tissue types (PERMANOVA F = 2.90,
p = 0.001), tumor and non-tumor (PERMANOVA F =
2.94, p = 0.001), and adenocarcinoma (AD) versus
squamous cell carcinoma (SCC) (PERMANOVA F = 2.27,
p = 0.005), with tumor vs. non-tumor having the largest
among-group distance denoted by the higher F value
(Fig. 1c–e). Similarly, we observed significant difference in
beta diversity between tumor and non-tumor (PERMA-
NOVA F = 3.63, p = 0.001) and AD v SCC (PERMANOVA
F = 27.19, p = 0.001) (Fig. 1f, g). Together, these data illus-
trate a trend of increasing diversity and richness associ-
ated with lung cancer.
A distinct group of taxa are enriched in squamous cell
carcinoma with Acidovorax more abundant in smokers
The two most common types of non-small cell lung can-
cer are SCC and AD, arising centrally from the cells lining
the bronchi and from peripheral airways, respectively. Pre-
vious studies report that the microbial community differs
between the bronchi and lower lungs in COPD [6]. This
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phenomenon of anatomic-specific microbial variation was
also apparent in the abundance of genera between bron-
chial and SCC tumors from the upper lungs with higher
abundance of Acidovorax in comparison to AD tumors
(Additional file 1: Figure S6). Further, the taxonomic dis-
tribution in AD tumors appears more similar to the taxo-
nomic abundance in COPD, which is generally dominated
by Pseudomonas [6]. Given this distinction, we controlled
for this potential confounder of lung location in subse-
quent analyses. This led us to investigate the specific taxo-
nomic pattern further and ask if there was a specific
microbial consortia that is enriched in SCC or AD tumor
tissue. In the NCI-MD study, we identified 32 genera that
were differentially abundant in SCC (n = 47) versus AD (n =
67) tumors (Student’s t-test; MW P < 0.05), nine of
which were significant after multiple testing correction
(FDR) (Acidovorax, Brevundimonas, Comamonas, Tepidi-
monas, Rhodoferax, Klebsiella, Leptothrix, Polaromonas,
Anaerococcus) (Fig. 2a). We also validated these same
observations in the TCGA dataset (AD = 485, SCC = 489)
(Mann–Whitney FDR corrected p value< 0.05) (Fig. 2b).
To control for potential confounders of this association,
including age, gender, race, smoking, anatomical location,
and stage, we conducted adjusted logistic regression
analysis in the NCI-MD study for each taxa separately and
confirmed 6/9 of these genera were significantly associated
with increased odds of being SCC as compared to AD
lung cancer (Fig. 2c, Additional file 1: Tables S5 and S7).
Though we had reduced power, we asked whether the
time since quitting smoking would change this associ-
ation, and found that Acidovorax, Klebsiella,Tepidimonas,
Rhodoferax, and Anaerococcus remained significant. When
we examined the larger TCGA dataset, we also found
significantly increased odds of being SCC as compared
with AD among 4/9 (Acidovorax, Klebsiella, Rhodoferax,
Anaerococcus) of the same genera in adjusted models
A C
D F
GE
B
Fig. 1 The bacterial profile and diversity of the lung microbiome in non-diseased and cancerous tissues. a 16S rRNA gene sequences from
non-diseased lung (ImA or HB; top), non-tumor adjacent (NT) and tumor (T) assigned to OTUs or proportional abundance of metatranscriptomic
sequences (TCGA; bottom) at the phylum level showing the most dominant taxa for each tissue type. b Alpha diversity between non-diseased
lung tissue (ImA and HB) non-tumor adjacent (NT) and tumors from 16S rRNA gene sequencing using Chao1 (richness) or inverse Simpson index.
*p < 0.05, **p < 0.01. Test of significance is Mann–Whitney. PCoA plots from NCI-MD study of tissue microbiome beta-diversity colored by (c) all
tissue types, (d) cancer cases, and (e) histological subtype; and from TCGA study of (f) cancer cases and (g) histological subtype. ImA immediate
autopsy, HB hospital biopsy
Greathouse et al. Genome Biology  (2018) 19:123 Page 5 of 16
(FDR corrected P < 0.05) (Fig. 2d, Additional file 1: Tables
S6 and S8). This association also remained significant after
adjusting for pack years and time since quitting smoking.
Together these data, validated in two separate cohorts,
demonstrate that a specific community of taxa is more
abundant in SCC as compared with AD lung cancer tissue,
and are capable of distinguishing between AD and SCC
tumors from individuals with similar exposure to cigarette
smoke. However, whether this is a cause or consequence of
the development of SCC cancer remains unknown.
Both SCC and AD lung cancers are associated with
smoking; however, the association between smoking and
SCC is stronger [30], which leads us to ask whether any of
the SCC-enriched taxa were also associated with smoking.
We stratified the tumor samples into never smokers (n = 7)
or ever-smokers (current [n = 70] and former smokers [n =
40]) using linear discriminant analysis (LEfSe) to identify
smoking-associated microbial biomarkers in SCC tumors.
We identified six genera that were able to distinguish ever
(former and current) versus non-smokers in our NCI-MD
study (Acidovorax, Ruminococcus, Oscillospira, Duganella,
Ensifer, Rhizobium) (Additional file 1: Figure S6C). Specific-
ally, Acidovorax was more abundant in former and current
smokers as compared with never smokers (Kruskal–Wallis
p value < 0.05) (Fig. 3a), with a similar trend observed in
the TCGA dataset (nnever = 120, nformer = 551, ncurrent = 217)
(Kruskal–Wallis p = 0.27; ANOVA p = 0.02). We did not,
however, observe any correlation between Acidovorax
abundance and smoking time cessation. Interestingly, the
relative abundance of Acidovorax and Klebsiella were
A
C D
B
Fig. 2 Taxonomic consortia differentiating smoking status and histological subtype of lung cancer. a Heat maps showing top differentially
abundant genera (NCI-MD) (Mann–Whitney p value < 0.05; * overlapping between NCI-MD and TCGA) between AD and SCC lung cancer tissue
sorted by histological subtype and smoking status. b Heat map showing genera (TCGA) that that are differentially abundant between AD and
SCC (Mann–Whitney FDR corrected p < 0.05), sorted by histological subtype and smoking. c Forest plot of odds ratios for genera in NCI-MD
dataset that are significantly associated with SCC compared to AD in tumors (adjusted odds ratio p < 0.05). d Forest plot of odds ratios for
species in the TCGA dataset that are significantly associated with SCC vs AD in tumors (adjusted odds ratio FDR corrected p < 0.05)
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higher in former and current smokers when we stratified
by histological subtype in both the NCI-MD and TCGA
datasets (Fig. 3b, Additional file 1: Figure S7), indicating not
only are there bacteria which have a higher relative abun-
dance in tumors from individuals who smoke, but SCC
tumors from smokers have even greater relative abundance
of these bacteria. We also demonstrated the presence of
this bacterium in lung tumors using FISH (Fig. 3c, d,
Additional file 1: Figure S8, Additional file 2), and using
PacBio sequencing, which identified the species as A.
temperans (Additional file 1: Table S4). We did not find any
significant associations between pack years or time since
quitting smoking and the abundance of these taxa in either
study among SCC tumors in either study.
TP53 mutations are associated with enrichment of SSC-
enriched taxa
The most prevalent somatic mutation in SCC lung tumors
is in the gene TP53 [31]. Previous studies demonstrate
that mutations in TP53, specifically in colon cancer, lead
to disruption of the epithelial barrier allowing the infiltra-
tion of tumor-foraging bacteria and resulting in disease
progression [17]. Given that TP53 mutations are found in
75–80% of SCC tumors, we hypothesized that these
A C
D
B
Fig. 3 Relative abundance of Acidovorax stratified by smoking status and histological subtype. a Relative abundance of Acidovorax stratified by
smoking status in the NCI-MD (left) and TCGA (right) datasets. b Relative abundance of Acidovorax in never, former, and current smokers stratified
by histological subtype in the NCI-MD (left) and TCGA (right) datasets. c Representative FISH images of tumor tissue sections using fluorescent
probe specific to Acidovorax. d Quantification of Acidovorax probe reactivity (10 fields; at least 300 cells counted) showing percentage (%) of cells
with perinuclear probe reactivity from two lung cancer cases (15,713 – SCC/current smoker; 20,172 – SCC/former smoker). *p < 0.05, **p < 0.01,
****p < 0.0001. Tests of significance are Mann–Whitney or Kruskal–Wallis and Dunn’s multiple comparisons test. NS non-significant
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SCC-associated taxa may be more abundant in tumors
with TP53 mutations, owing to the loss of the epithelial
barrier function in these tumors. To address this question,
we investigated the association between TP53 mutations
in both the NCI-MD (n = 107) and TCGA (n = 409)
datasets using either TP53 specific sequencing (MiSeq) or
the published TP53 mutation analysis data from TCGA
[31]. We first analyzed all tumors in the NCI-MD study
regardless of histology and identified a group of taxa that
were more abundant in tumors with TP53 mutations
(Fig. 4a). To have greater power, we performed the same
analysis in the TCGA dataset and observed a significant
increase in these same taxa (MW FDR corrected P < 0.05)
(Fig. 4b). When analyzing only SCC tumors (n = 46), this
signature became stronger in tumors with TP53 mutations
in both datasets, specifically among the SCC-associated
taxa previously identified (Fig. 4c, d). In the NCI-MD
study, we found that 5/9 of the genera (Acidovorax, Kleb-
siella, Rhodoferax, Comamonas, and Polarmonas) that dif-
ferentiated SCC from AD were also more abundant in the
tumors harboring TP53 mutations, though not statistically
significant (Fig. 4c). In the TCGA dataset, the fold change
in all five SCC-associated genera were significantly higher
in SCC tumors (n = 177) with TP53 mutations (MW cor-
rected FDR < 0.01; Fig. 4d). Furthermore, using these same
SCC-associated taxa we observed no pattern of associ-
ation in AD tumors with TP53 mutations indicating this
signature was specific to SCC with TP53 mutations
(Additional file 1: Figures S9A and S9B). Overall, these
data are consistent with the hypothesis that mutations in
TP53 are associated with the enrichment of a microbial
consortia that are highly represented in SCC tumors.
Discussion
Gene-environment interactions have been identified as
contributors to cancer incidence [32]; however, little is
known about gene-microbiome interactions in carcino-
genesis. We demonstrate a gene-microbiome association
in human lung cancer as well as histological evidence of
a smoking-associated bacterium, Acidovorax. Herein, we
identify a microbial consortia that is associated with a
histological subtype of lung cancer, SCC, which is fur-
ther enriched in tumors with mutations in TP53. Given
the strong association between smoking and develop-
ment of SCC, it follows that a subgroup of this SCC
consortium would also be found in smoking-associated
SCC. We validate this assumption finding Acidovorax
spp. more abundant in SCC tumors harboring TP53
mutations and confirmed the presence of this genus
histologically. These results suggest that smoking to-
gether with tumorigenesis may provide an environment
conducive to the growth of Acidovorax spp. and similar
species, which can flourish in nutrient-depleted environ-
ments, such as that of the lung. Collectively, these
observations indicate that a state of dysbiosis exists in
lung cancer. The hypothesis generated is that epithelial
cells in the lung exposed to tobacco smoke and/or muta-
tions in TP53 are invaded by species that take advantage
of this new microenvironment, suggesting these bacteria
could act as promoters in lung tumorigenesis.
Several cancers are caused by bacteria and viruses,
including cervical cancer (HPV), liver cancer (HBV), and
gastric cancer (H. pylori and potentially B. fragilis); how-
ever, very few microbes have been identified as carcino-
genic. Beyond acting as initiators, other relationships exist
between microbe and host tissue environments, in a simi-
lar manner to chemical carcinogens. These relationships
include bacteria that act as promoters and those that are
just passengers in the tumorigenesis process. While this
study is not longitudinal, our data suggest the latter two
possibilities, either they are promoters or passengers.
In support of the promoter hypothesis, it is plausible
that smoking creates an environment that allows these
bacteria to outcompete other species for resources and
thus survival, which allows exposure to microbial factors
enhancing tumorigenesis. Smoking is most strongly asso-
ciated with the SCC histological subtype of lung cancer;
however, whether smoking alters the lung tissue micro-
biome is still not well understood, especially in the context
of disease. Multiple studies using various samples tissue
and non-tissue types (e.g. oral and/or nasal swabs, bron-
chial lavage fluid, or lung tissue) have found inconsistent
results in alpha diversity by smoking status. From our
study, while we did not observe differences in alpha diver-
sity, we observe a significant difference in the taxonomic
consortia among smokers as compared to non-smokers,
specifically in Acidovorax and Klebsiella spp. Similarly,
oral and nasal microbial taxa differences have been ob-
served between smokers and non-smokers [29, 33]. From
a large study of the naso- and oropharynx, significant dif-
ferences in specific microbial taxa were identified between
smokers and non-smokers [34]. Additionally, in a study of
non-malignant lung tissue (n = 152), they observed a
significant increase in alpha diversity with higher number
of pack years of smoking [35]. While they identified
Acidovorax, Anaerococcus, and Comamonas in smokers,
these taxa did not differentiate smokers and non-smokers
in a healthy population. However, in a recent study of
non-malignant lung tissue, which compared tissue to
isolated extracellular vesicles (EVs) from tissues, the
greater diversity was identified specifically in EVs, with a
greater abundance of Acidovorax specifically found in the
EVs of smokers, indicating a possible factor in differential
findings observed among previous studies [36].
These data indicate that smoking alone may be insuffi-
cient to alter the microbial population in a healthy popula-
tion. However, smoking has been shown to suppress the
immune system and induce epithelial barrier dysfunction
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[37]. Specifically, Acidovorax spp. have been identified in
two common brands of cigarettes [38] and have the cap-
acity to metabolize multiple organic pollutants like those
found in cigarette smoke [39]. Therefore, degradation of
tobacco smoke compounds, such as polycyclic aromatic
hydrocarbons by Acidovorax spp., may promote survival
of transformed cells and subsequently tumor promotion.
These factors may allow taxa direct access to epithelial cells
where microbial toxins or reactive oxygen/nitrogen from
the aforementioned species to directly or indirectly encour-
age malignant transformation of the lung epithelium via
DNA damage and mutations in TP53 [40–42]. Once the
epithelial barrier defense is lost as a consequence of muta-
tions in TP53 and malignant transformation, these species
then may become tumor-foraging bacteria. In support,
several bacterial species have been shown to modulate the
tumor-suppressor p53 at both the protein and DNA level
[43]. Specifically, the loss of p53 in enterocytes in murine
models impairs the epithelial barrier and allows infiltration
of bacteria resulting in NF-κB signaling, which was required
for tumor progression [17]. This evidence suggests that
SCC tumors with TP53 mutations could have poor
A B
C D
Fig. 4 Mutations in TP53 associated with abundance of taxonomic signature specific to squamous cell lung tumors. a Heat map of genus-level
abundance in NCI-MD data colored by mutation status, TP53 wild-type or mutated, smoking, and histological subtype in all lung tumor samples.
b Heat map of genus-level abundance from TCGA data in all tumors colored by mutation status, TP53 wild-type or mutated, smoking, and
histological subtype. c, d Fold change in mean abundance of SCC-associated taxa in NCI-MD or TCGA tissues comparing TP53 mutated to wild-
type. Test of significance is Mann–Whitney. Fold change among all taxa in (d) are significant after FDR correction < 0.01. (NCI-MD; SCCwt = 11,
SCCmut = 35 and TCGA; SCCwt = 59, SCCmut = 118)
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epithelial barrier function, thus allowing tumor foraging
bacteria, such as those identified in our study, to become
more abundant in tumors with TP53 mutations. The coun-
terfactual is also possible. Similar to the B. fragilis toxin
ETBF, which is genotoxic and initiates colon carcinogenesis
in animal models [44], one or more of the tumor-associated
species may induce TP53 mutations. Notably, individuals
harboring mutations in TP53 with stage I SCC also have
poorer prognosis [45], thus it will be important to deter-
mine if any of the species enriched in SCC are functionally
related to reduced survival or simply biomarkers of a
diminished mucosal barrier function. Whether any of these
bacteria are promoting SCC tumorigenesis or inducing
mutations in TP53 is currently under investigation.
In support of the passenger hypothesis, our study indi-
cates that smoking is associated with alterations in rela-
tive abundance of species in SCC tumors. The number
one risk factor for lung cancer is tobacco exposure and
is a known factor in chronic lung inflammation. Tobacco
and cigarette smoke contain bacterial products (i.e. LPS)
that can cause inflammation, impaired barrier function,
and potentially alter the microbiome to influence lung
carcinogenesis [8, 46, 47]. Additionally, tobacco leaves
harbor both mold and potentially pathogenic bacteria
that can be transferred in a viable form into the respira-
tory tract on tobacco flakes inhaled in mainstream
smoke [46, 47]. Further, biologically significant quantities
of bacteria are microaspirated daily in healthy individ-
uals [48] and thus is possible for these species to accu-
mulate in a pathogen-friendly environment but may not
ultimately contribute to tumorigenesis. Nevertheless,
future studies should address this issue mechanistically.
The strength of our findings includes the large number
of individuals sampled in this study, use of two separate
sample populations, two sets of control populations, two
separate sequencing methodologies (MiSeq and PacBio),
and microscopic validation (FISH) of the species in lung
tumor tissue. We have also been diligent in assessing the
possibility of contaminating taxa being an artifact of
sample collection or sample processing by extensive
quality control analysis of sequencing, sequencing across
two different platforms, and microscopy. Given the low
biomass of these samples, however, we were not able to
completely eliminate all contaminants and acknowledge
that this may skew the results. While we were able to
control for antibiotic exposure in the NCI-MD study, we
acknowledge a limitation of the validation study is the
inability to control for antibiotic exposure in the TCGA
dataset and ImA controls, as well as, significant differ-
ences in clinical features between the cancer cases and
controls, which could be confounders. However, in a re-
cent study of the microbiome of endoscopic gastric biop-
sies, confirmation of multiple shared bacteria in clinical
samples, specifically H. pylori, was demonstrated using the
TCGA RNA-seq data with methods similar to those pre-
sented in our study [49].
Conclusions
With the majority of lung cancer being diagnosed at a late
stage, the recent advancement in the treatment of late stage
(III/IV) lung cancer with immune checkpoint inhibitors tar-
geting PD-1, nivolumab, has resulted in a 40% reduced risk
of death as compared to standard chemotherapy [50]. The
response rate, however, is still not complete for these pa-
tients. Important insights into understanding the differen-
tial response rates of this new immunotherapy has
suggested the composition of the lung microbiome before
therapy as a key player in therapeutic effectiveness [51].
Given our results demonstrating alterations in the micro-
bial composition in lung cancer that are histology and
mutation specific, future studies should address whether
the lung or nasal microbiome composition improves the
stratification of patients who would be most responsive to
immunotherapy. This suggestion is supported by recent
animal studies demonstrating the contribution of the gut
microbiome to the effectiveness of immunotherapy [52].
With these results, we foresee a new avenue for mechanis-
tic studies to address the role of microbe-host relationship
in lung cancer inflammation, response to therapy, and
microbial engineering for drug delivery.
Methods
Sample populations and datasets
Samples used for DNA extraction, polymerase chain
reaction (PCR) and sequencing were obtained from the
ongoing NCI-MD study (seven hospitals participating in
the greater Baltimore, MD area recruited during 1999–
2012), as described previously [53], from which 398 lung
cancer cases were obtained, and included both tumor and
non-tumor adjacent, with 121 matched pairs. The final
sample set used for analysis after sequencing, which
contained 106 matched pairs after quality control, is found
in Table 1. Lung tumors and paired non-tumor adjacent
samples from the NCI-MD study were obtained at the
time of surgery, from which a section of tumor and
non-involved adjacent lung tissue from the same lung
resection were flash frozen and stored at − 80 °C, with an
estimated time to cold ischemia of 66 min. At the time of
study entry, a detailed patient interview was conducted to
obtain basic clinical information in addition to previous
cancers, neoadjuvant therapies, current medications,
family history of cancer, smoking history, education level,
and financial status. Staging was assigned using the
Cancer Staging Manual of the American Joint Committee
on Cancer (AJCC) 7th edition. Preoperative antibiotics
were administered for those cases recruited after 2008 and
any antibiotic oral medication use was controlled for as a
covariate for all statistical analysis in model testing;
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however, these data were not available for immediate aut-
opsy (ImA) non-cancer samples. Controls representing
non-cancerous tissue were obtained from the Lung
Cancer Biorepository Research Network (n = 16; hospital
controls). Theses samples were obtained as frozen lung
specimens from individuals who had a previous positive
nodule identified by PET scan and subsequently under-
went tissue biopsy, which was ruled benign. The average
non-operative ischemia time was 34 min (16–70 min) for
these samples. Clinical information included those listed
above as well as smoking history, antibiotic usage (Y/N),
and disease diagnosis. Two cases had emphysema at the
time of biopsy and were not used in the analyses.
Immediate autopsy (ImA) samples obtained from the
University of Maryland (UMD) hospital, which is part of
the NCI-MD study population (n = 41; population con-
trols) (Table 1). Lung tissue from ImA was received frozen
from the UMD biorepository and served as the population
controls for non-cancer lung tissue. Briefly, samples from
ImA were obtained within minutes (< 30 min) after death
and put on ice for < 30 min during dissection before cold
ischemia at − 80 °C. All ImA subjects underwent extensive
autopsy and were determined to be cancer-free. Demo-
graphic information included age, gender, race, and cause
of death only. Non-smokers in the NCI-MD study were
categorized as having smoked < 100 cigarettes or < 5 packs
over a lifetime, whereas smokers were categorized as
current smokers or formers smokers, who had quit
for > 6 months. Sequences derived from RNA-seq of lung
tumor (n = 1006) or non-tumor adjacent tissue (n = 106)
were obtained from TCGA (N = 1112) for validation of
the NCI-MD study16S rRNA gene sequencing analysis
and results. Due to the fact that all RNA-seq data in
TCGA were obtained using poly-A capture, any microbial
data from this analysis will necessarily be biased. For this
reason, we only used these data as validation of results
first identified in our 16S rRNA gene sequencing analysis.
Public data, including all clinical patient information
(Table 1), was downloaded from the Data Matrix on the
TCGA website, https://portal.gdc.cancer.gov. The raw
data in the form of BAM and FastQ files were download
from a secure server at CGHUB and access was applied
for and approved for raw data downloads by University of
California Santa Cruz, https://cghub.ucsc.edu/. The files
were downloaded and stored in archived format and sub-
sequently un-archived for analysis. The results shown here
are in whole or part based upon data generated by the
TCGA Research Network: https://gdc.cancer.gov.
DNA extraction and 16S rRNA gene sequencing
DNA from lung cancer and control lung tissues was iso-
lated according to a tissue-modified version of the standard
Human Microbiome Project’s DNA isolation procedure.
Genomic DNA from frozen lung tissue was extracted after
tissue homogenization in Yeast Cell Lysis Buffer (Epicenter)
containing lysozyme (Epicenter) by bead beating (TissueLy-
ser II) with proteinase k (Invitrogen). DNA was purified
with the Life Technologies PureLink kit according to the
manufacturer’s protocol (Invitrogen). A sterile water con-
trol (MoBio) was also processed along with all frozen tissue
and used as background contamination control for DNA
isolation, PCR, and sequencing. Background contamination
controls for tissue collection, pathology, and sequencing
were also collected through routine swabs after surgery and
sequenced in conjunction with tissue samples. Specifically,
the NCI-MD study tissues were isolated in a laminar flow
hood to minimize contamination for downstream applica-
tions, using sterile forceps and gloves. Controls for contam-
ination points during surgical tissue collection and
pathological assessment included swabs from inside of the
surgical tissue collection vessel before/after, pathology cut-
ting board before/after, pathology knife blade before/after,
gloves before/after, and pathology ink bottle rim and collec-
tion tube for freezing before/after (Additional file 3). Briefly,
swabs were dipped in Yeast cell Lysis buffer and area/object
swabbed, then the swab was broken off into tube and
frozen at − 80 °C. A negative control was also collected
using 50 μL of MoBio PCR water as a mock sample
(PCR_NC) and processed through DNA extraction with tis-
sues to assess contamination from reagents, which was ana-
lyzed on three separate runs of MiSeq. The positive control
was the High Even Mock Community (Broad Institute),
which was also sequenced on three separate runs of MiSeq.
The negative and positive control samples were spiked into
four MiSeq runs at a similar concentration to that of the
NCI-MD samples. To control for false grouping or batch
affects, we randomized the tissue sample types (NT, T, and
ImA) (with the exception of HB controls) across five separ-
ate sequencing runs of MiSeq (Additional file 4). The fifth
plate consisted of duplicate samples and samples that had
failed sequencing on previous runs of MiSeq.
Sequencing for the 16S rRNA gene was performed
with 40 ng of sample DNA from 398 cases and 57
controls using primers for variable region V3–V5 with
16S rRNA gene sequence-specific portions based on
Kozich et al. [54] with adapters for subsequent addition
of standard Illumina dual indexes. PCR was performed
using a Phusion DNA Polymerase High Fidelity kit
(ThermoFisher). The cycling conditions were as follows:
98 °C for 2 min, then 36 cycles of 98 °C for 15 s, 60 °C
for 1 min 40 s, and 74 °C for 1 min. PCR products were
purified using the Agencourt AMPure XP kit according
to the manufacturer’s instructions (Beckman Coulter).
Second round PCR with Illumina dual-index oligos was
performed using a Phusion DNA Polymerase High Fidelity
kit (ThermoFisher) as following: 98 °C for 2 min, then
six cycles of 98 °C for 15 s, 72 °C for 20 s, and 72 °C for
1 min. Samples were pooled and purified using Agencourt
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AMPure XP. Sequencing was conducted on Illumina
MiSeq instrument using v3 600 cycles kit (Additional file 1:
Supplemental Methods).
Full-length 16S rDNA PCR reactions (PacBio)
Full-length 16S amplifications were performed using:
1 μL of total DNA as template; 0.25 μM of the universal
16S primers F27 and R1492 with four different sets of
asymmetric barcodes at (Additional file 1: Table S9). and
GoTaq Hot Start Master Mix (Promega) in a 50 μL final
volume. Cycling conditions were: 94 °C, 3 min; 35 cycles
of 94 °C 30 s, 54 °C 30 s, 72 °C 2 min; following by a
5 min final elongation at 72 °C. PCR products were
cleaned with AxyPrep™ MagPCR (Corning Life Sciences)
according to the manufacturer’s protocol and eluted in
40 μL of water. Cleaned PCR products were quantified
using the Bio-Rad QX200 droplet digital PCR (Bio-Rad)
and QX200 EvaGreen® Supermix with primers F357 and
R534 (Additional file 1: Table S10) targeting the V3 vari-
able region of 16S rDNA. Based on the results, amplicon
libraries were normalized to the same concentration
before pooling. Pooling was always performed using
amplicon libraries with distinct barcodes. Multiplexing
was performed with 2–4 libraries per pool.
Pacific biosciences circular consensus sequencing
Sequencing library construction was accomplished using
the Pacific Biosciences (PacBio) SMRTbell™ Template
Prep Kit V1 on the normalized pooled PCR products.
Sequencing was performed using the PacBio RS II
platform using protocol “Procedure & Checklist - 2 kb
Template Preparation and Sequencing” (part number
001–143-835- 06). DNA Polymerase Binding Kit P6 V2
was used for sequencing primer annealing and polymer-
ase binding. SMRTbell libraries were loaded onto
SMRTcells V3 at a final concentration of 0.0125 nM
using the MagBead kit, as determined using the PacBio
Binding Calculator software. Internal Control Complex
P6 was used for all reactions to monitor sequencing
performance. DNA Sequencing Reagent V4 was used for
sequencing on the PacBio RS II instrument, which
included MagBead loading and stage start. Movie time
was 3 h for all SMRTcells. PacBio sequencing runs were
set up using RS Remote PacBio software and monitored
using RS Dashboard software. Sequencing performance
and basic statistics were collected using SMRT® Analysis
Server v2.3.0. De-multiplexing and conversion to FastQ
was accomplished using the Reads of Insert (ROI) proto-
col in the SMRT portal v2.3 software. Only reads with a
minimum of five circular passes and a predicted accur-
acy of 90 (PacBio score) or better were used for further
analysis. Each read was labeled in the header with the
number of CCS (circular consensus sequence) passes
and the sample designation using a custom ruby script,
followed by concatenation of all reads into a single file
for subsequent filtering and clustering.
Filtering and OTU clustering of 16S rRNA gene sequence
data
Initial screening for length and quality using QIIME v 1.9.0
(qiime.org) [55]. Reads containing more than five consecu-
tive low-quality base calls (Phred < Q20), were truncated at
the beginning of the low-quality region. Due to the low
quality of the majority of R2 reads (Phred < Q20 and
< 150 bp length), we used the R1 reads only for this ana-
lysis. Passing sequences were required to have
high-quality base calls (≥ Phred Q20) along a minimum of
75% of the read length to be included. The average Phred
score per read was 34 with 88% of reads having a Phred
score > 30 (Additional file 1: Supplemental Methods,
Figure S1, and Table S2). After primer removal, final
sequences containing ambiguous bases (Ns) or lengths
< 150 bp were removed. High quality sequences were
then screened for spurious PhiX contaminant using
BLASTN with a word size of 16. Reads were then assessed
for chimeras using USEARCH61 (de novo mode, 97%
identity threshold for clustering). Non- chimeric sequences
were screened for contaminant chloroplast and mitochon-
dria using the RDP naïve Bayesian classifier, as well as
non-specific human genome contaminant using Bowtie2
against the UCSC hg19 reference sequence. Finally, se-
quences were evaluated for residual contaminants using
BLASTN searches of the GreenGenes database (v13.5). Fil-
tered reads included those not matching any reference
with at least 70% identity along 60% of their length. Ex-
ploratory assessment using BLASTN searches against the
NCBI NT database indicated the majority unknown con-
taminant reads were amplified human genome sequence.
High-quality passing sequences were subsequently clus-
tered into operational taxonomic units using the
open-reference operational taxonomic unit (OTU) picking
methodology implemented within QIIME using default pa-
rameters and the GreenGenes database (99% OTUs) sup-
plemented by reference sequences from the SILVA
database (v111). Before downstream diversity analyses, the
OTU table was rarefied to 5500 sequences per sample. Be-
fore diversity analysis, contaminants were removed and
again OTUs table rarified to 5500 sequences per sample.
Alpha diversity estimators and beta-diversity metrics were
computed in QIIME with differential abundance analyses
performed in R. In order to determine significant differ-
ences in beta diversity, we used the adonis function in the
R package vegan to conduct PERMANOVA with Bray
Curtis distance and 999 permutations in order to be able
to compare across studies. All sequences from the MiSeq
and PacBio datasets have been deposited at the following
location: http://www.ncbi.nlm.nih.gov/bioproject/320383.
See Additional file 1: Supplemental Methods for details
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regarding PacBio sequence processing, and Additional file 5
for complete OTU and Additional file 6 for Pathoscope
results.
TCGA RNA-seq data processing and alignment
In order to analyze all RNA-seq unmapped reads from
TCGA lung cancer samples, we developed a custom
metagenomic analysis pipeline using (1) MetaPhlAn2,
(2) Kraken, and (3) Pathoscope [22]. First, all reads were
filtered for quality using Trimmomatic (v0.32, minimum
average quality > 20 over a 5-bp sliding window, mini-
mum final length 3 28 bp) and searched for potential
PhiX-174 contaminant using Bowtie2. Reads passing this
filter were then mapped to the comprehensive NCBI
Homo sapiens Annotation (Release 106) using Bowtie2
to remove any human-associated reads. The resulting
non-human read set was then taxonomically assigned
using (1) MetaPhlAn2, (2) Kraken, and (3) Pathoscope
in parallel to evaluate consistency in the resulting pro-
files. Assignments from each method were aggregated at
higher taxonomic levels (genus and species) for down-
stream statistical comparisons (Additional file 1: Table
S2). The results from Pathoscope and its validation in
other studies lead us to use these data for the remainder
of the downstream analysis.
Alpha diversity estimators and beta-diversity (Bray Cur-
tis) metrics were computed in QIIME using genus and
species level assignments with differential abundance ana-
lyses performed in R and Stata (v13). Full taxonomic as-
signments for each sample are provided in Additional file 5.
Statistical analysis and classification of taxa associated
with lung cancer
Statistical analysis and visualization, ANOVA and PCoA,
was performed on sequencing quality metrics by popula-
tion sample type (ImA, HB, NT, and T) (Additional file 1:
Figure S1). Alpha- and beta-diversity metrics were com-
puted in QIIME with differential abundance analyses
performed in R and Stata (v13). Mann–Whitney tests
corrected for multiple testing (Benjamini–Hochberg
[FDR]) were used to conduct initial comparisons be-
tween tissue type and histological subtype (AD or SCC)
followed by multivariable logistic regression controlling
for multiple confounders (age, gender, race, smoking
status, stage, antibiotic exposure, lung location, average
Phred score, and sequencing run) (Additional file 1:
Table S11). An additional logistic regression model was
constructed to estimate the odds of AD versus SCC for
each taxa separately (identified from the initial testing)
stratified by TP53 mutation status (wild-type versus
mutated) with and interaction term between the taxa
and mutation added to the model. See Additional file 1:
Supplemental Methods for details of statistical modeling.
TP53 gene sequencing and mutation analysis
Genomic DNA extracted from lung cancer tissues (n =
107) was submitted for TP53-targeted sequencing using
the MiSeq Illumina platform. For mutation analysis, 46
samples were SCC. The assay was targeted at the exons
and proximal splice sites. Forward and reverse primers
were tailed with Illumina Adapter tags for downstream
next-generation sequencing using the BioMark HD
System (Fluidigm) and Access Array IFC chips and kits
(Fluidigm). PCR products were indexed using an 8-mer
oligo barcode. See Additional file 1: Table S3 lists
sequences for primers used in the sequencing assay.
Sequence results were processed and aligned to human
genome and underwent QC requiring coverage > 100
reads with the variant (most single nucleotide variants
[SNVs] had a read depth in the thousands) and mini-
mum allele frequency > 10%. The 100-level cutoff for
coverage allows to detect variations if the tumor fraction
> ~ 20% with 95% confidence, under the assumption of a
diploid genome. The 10% allele frequency cutoff is
derived from that same consideration. The variants
called included all common polymorphisms. Because
only the tumor was sequenced, in order to score somatic
mutations, those deemed to be germline were filtered
out. These included SNVs present in dbSNP with high
reported allele frequency (common polymorphisms).
Also, SNVs in untranslated regions and introns were not
considered, as their somatic status and functional
implications are unclear. The presence of putative
somatic exonic and splicing variants was corroborated in
the TCGA and COSMIC datasets. See Additional file 1:
Table S2 for details.
Fluorescent in situ hybridization analysis of Acidovorax
In order to confirm the presence Acidovorax in lung
tumor tissue, fluorescently labeled probes were created for
each bacterium. Genus or species-specific bacteria probes
were hybridized using tumor tissues in addition to gram
stain on each. Tumor tissues from cancer cases were fixed
in OCT and sectioned frozen (10 μm). Before fixation in
4% paraformaldehyde, sections were thawed at RT. Sec-
tions were washed in PBS and the probe (2 μL) was added
to 90 μL FISH buffer (0.9 M NaCl, 0.02 M Tris pH 7.5,
0.01% SDS, 20% formamide). This solution was added to
the section (20–100 μL) and placed in the hybridization
chamber (46 °C) for 3–18 h depending on probe used.
Section were washed twice (wash 1: 0.9 M NaCl, 0.02 M
Tris pH 7.5, 0.01% SDS, 20% formamide; wash 2: 0.9 M
NaCl, 0.02 M Tris pH 7.5, 0.01% SDS) and incubated at
48 °C for 15 min. Slides were then dried for 10 min. Before
visualization, DAPI and Vectashield were added to the
slides. The probe used for FISH was: Acidovorax (CTT
TCG CTC CGT TAT CCC, 5′ modification: Alexa Fluor
532). Representative fields were imaged using Zeiss 710
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and a 100X objective for the probe. In addition to
two-dimensional (2D) images, Z stacks were also obtained
for each bacterial probe and used to reconstruct
three-dimensional (3D) images and movies using Imaris
software. Quantification of Acidovorax probe reactivity
was conducted using ten 2D fields of two patients. At least
300 cells were counted per patient. Percentage (%) of cells
with perinuclear probe reactivity was quantified using
ImagePro Plus 6.0 software (Additional file 1: Figure S8).
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